Czechia

Earlier drafts of this page recorded ownership as evidenced but uncited. That gap is now closed, and the commonly repeated citation was wrong.

The operative provision is §16 of zákon č. 372/2011 Sb., the act on health services. A právnická osoba, a legal entity, may hold the oprávnění k poskytování zdravotních služeb for pharmacy care, on condition that it appoints an odborný zástupce: a registered pharmacist with the required professional competence who is answerable for the professional conduct of the pharmacy. Zákon č. 378/2007 Sb., which is cited across secondary sources as the ownership rule, is the medicines act and governs handling of medicinal products, not who may own a pharmacy.

There is no multiplicity cap. Dr.Max, ultimately owned by the private equity house Penta Investments, runs the largest chain in the country, and Pilulka and BENU both operate at scale. For a foreign non-pharmacist founder this is one of the cleanest ownership environments in the EU.

SÚKL’s LEK-16 verze 7, issued January 2026, is unambiguous. Mail-order dispensing is limited to medicinal products whose marketing authorisation does not restrict supply to prescription. Prescription medicines, narcotics and psychotropics, compounded preparations and bulk substances are all excluded by name.

Compliant mail-order pharmacies must display the EU common logo, maintain a staffed information service, deliver within three days, monitor cold-chain temperature in transit and retain records for five years. None of that helps a GLP-1 operator, because the product class is excluded before those obligations apply.

Prescription fulfilment therefore has to be in person or click-and-collect at a physical pharmacy.

Poland built a large questionnaire-prescribing industry on top of an e-prescription system. Czechia has a comparable e-prescription system and more permissive ownership, and yet no equivalent market exists. The answer is the redemption step.

A Czech eRecept is issued as an identifikátor, a code the patient presents at a pharmacy. Because Rx mail order is banned, that presentation is physical. The patient has to walk into a pharmacy regardless, which removes most of the convenience premium a telehealth front end sells. In Poland the same code can be filled at a pharmacy the patient was going to visit anyway, but the prescribing itself was the scarce good; in Czechia physician access is not the bottleneck to the same degree, and cross-border remote prescribing into the Czech system is not established.

The absence is a structural consequence, not untapped whitespace. Treat any plan predicated on being first with a Czech receptomat with suspicion.

Ozempic is reimbursed for type 2 diabetes only, with conditions: HbA1c at or above 53 mmol/mol despite metformin, BMI at or above 30 or established cardiovascular risk, and prescription by an endocrinologist or diabetologist. Insured co-pay lands roughly in the 300 to 800 CZK range per pen. Uninsured Ozempic runs roughly 2,800 to 3,600 CZK per pen depending on strength.

Wegovy and Mounjaro carry no obesity reimbursement at all. Granular verified CZK retail prices for both proved hard to source, and the numbers circulating on comparison sites should be treated as indicative only.

The practical shape of the market is a cash-pay weight-loss segment served through physical pharmacies, with a specialist gate on the only reimbursed molecule.